Low-density lipoprotein composition and oxidability in atherosclerotic cardiovascular disease

Clinical Biochemistry

Volumn 29, Issue 5, 1996, Pages 479-487

  Schreier, Laura E ^b   Sanguinetti, Silvia ^b   Mosso, Hector ^b   Lopez, Graciela I ^b   Siri, Leticia ^b   Wikinski, Regina L W ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b NONE

Author keywords

atherosclerosis; chemical composition; cutoff values; LDL oxidability

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; KINETICS; LIPID COMPOSITION; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0037670485     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(96)00069-0     Document Type: Article

References (42)

1. 1. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488-500.
2. 2. Yla-Herttuala S, Palinski W, Rosenfeld M, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95.
3. 3. Shen M, Krauss R, Lindgren F, Forte T. Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res 1981; 22: 236-44.
4. 4. Nigon F, Lesnik P, Rouis M, Chapman M. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the celular LDL receptor. J Lipid Res 1991; 32: 1741-53.
5. 5. Steinberg D, Parthasarathy S, Carew T, Khoo J, Witztum J. Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 1989; 320: 915-24.
6. 6. Fogelman A, Shechter I, Seager J, Hokom M, Child J, Edwards P. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980; 77: 2214-8.
7. 7. Auwerx J, Marzetta C, Hokanson J, Brunzell J, Large Buoyant LDL like particles in hepatic lipase deficiency. Arteriosclerosis 1989; 9: 319-25.
8. 8. De Graaf J, Hak-Lemmers H, Hectors M, Demacker P, Hendriks J, Stalenhoef A. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298-306.
9. 9. Berliner J, Territo M, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85: 1260-6.
10. 10. Hessler J, Morel D, Lewis J, Chisolm G. Lipoprotein oxidation and lipoprotein-induced cytotoxity. Arteriosclerosis 1983; 3: 215-22.
11. 11. Yagi K. A simple fluorometric assay for lipid peroxide in blood plasma. Biochem Med 1976; 15: 212-6.
12. 12. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Comms 1989; 6: 67-75
13. 13. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992; 339: 1183-6.
14. 14. Andrews B, Burnand K, Paganga G, et al. Oxidisability of low density lipoproteins in patients with carotid or femoral artery atherosclerosis. Atherosclerosis 1995; 112: 77-84.
15. 15. Chiu H, Jeng J, Shieh S. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. Biochim Biophys Acta 1994; 1225: 200-8.
16. 2. Clin Chem 1983; 29: 2026-30.
17. 17. Wieland H, Seidel D. A simple specific method for precipitation of low-density lipoproteins. J Lipid Res 1983; 24: 904-8.
18. 18. Schumaker V, Puppione D. Sequential flotation ultracentrifugation. In: Segrest J, Albers J, Eds. Methods in Enzymology. Pp. 155-60. London: Academic Press, 1986.
19. 19. Noble R. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968; 9: 693-700.
20. 20. Bartlett G. Phosphorus assay column chromatography. J Biol Chem 1975; 193: 265-75.
21. 21. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein-dye binding. Anal Biochem 1976; 72: 248-54.
22. 1 and B by electroimmunoassay. Clin Chem 1982; 28: 59-62.
23. 23. Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem 1993; 39: 2522-6.
24. 24. Knapp R, Clinton Miller M. Defining normality using the predictive value method. In: Knapp R, Clinton Miller M, Eds. Clinical epidemiology and biostatistics. Pp. 53-60. Baltimore, MD: Williams & Wilkins, 1992.
25. 25. Demant T, Carlson L, Holmquist L, et al. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 1988; 29: 1603-11.
26. 26. Rosental S, Schreier L, Halperin H et al. Lipoproteína de baja densidad rica en triglicéridos y actividad de lipasa hepática en pacientes diabéticos insulino-dependientes. Medicina 1995; 55: 317-23.
27. 27. Schreier L, Wikinski R. Production of low density lipoprotein like particles by rat hind limb perfused with very low and intermediate density lipoproteins. Diab Nutr Metab 1993; 6: 3-12.
28. 28. Zambon A, Austin M, Brown G, Hokanson J, Brunzell J. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993; 13: 147-53.
29. 29. Eisenberg S. Lipoprotein abnormalities in hypertriglyceridemia: Significance in atherosclerosis. Am Heart J 1987; 2: 555-61.
30. 30. Aviram M, Bierman EL, Chait A. Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 1988; 263: 15416-22.
31. 31. Aviram M, Lund-Katz S, Phillips M, Chait A. The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J Biol Chem 1988; 263: 16842-8.
32. 32. Vega G, Grundy S. Comparison of apolipoprotein B to cholesterol in low density lipoproteine of patients with coronary heart disease. J Lipid Res 1984; 25: 580-92.
33. 33. Sniderman A, Wolfson C, Teng B, Franklin F, Bachorik P, Kwiterovich P. Association of hyperapobetalipoproteinemia with endogenous hypertiglyceridemia and atherosclerosis. Ann Intern Med 1982; 97: 833-9.
34. 34. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich P. Assocation of coronary atherosclerosis with hyperapobetalipoproteinemia increased protein but normal cholesterol levels in human plasma low density (β) lipoproteins). Proc Natl Acad Sci USA. 1980; 77: 604-8.
35. 35. Kwiterovich P, White S, Forte T, Bachorik P, Smith H, Sniderman A. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. Arteriosclerosis 1987; 7: 211-25.
36. 36. Roheim P, Asztalos B. Clinical significance of lipoprotein size and risk for coronary atherosclerosis. Clin Chem 1995; 41: 147-52.
37. 37. Chait A, Brazg R, Tribble D, Krauss R. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350-6.
38. 38. Esterbauer H, Jürgens G, Quehenberger O, et al. Autoxidation of human low density lipoprotein: loss of Polyunsaturated fatty acids and vitamin E and generation of aldehydes. J. Lipid. Res. 1987; 28: 495-509.
39. 39. Janero D. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radical Biol. Med. 1990; 9: 515-40.
40. 40. Kleinveld H, Hak-Lemmers H, Stalenhoef A, Demacker P. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992; 38: 2066-72.
41. 41. Maggi E, Chiesa R, Melissano G, et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994; 14: 1892-9.
42. 42. Croft K, Dimmitt S, Moulton C, Beilin L. Low density lipoprotein composition and oxidizability in coronary disease: apparent favourable effect of beta blockers. Atherosclerosis 1992; 97: 123-30.